Table 3.
Health care costs measured PPPM during the 12 months of follow‐up
| Ixekizumab (N = 496) | |
|---|---|
| All‐cause health care costs, mean (SD) | |
| Total (unadjusted) | $7638 ($5370) |
| Inpatient admissions | $396 ($4271) |
| Outpatient services | $811 ($1570) |
| All outpatient pharmacy | $6431 ($2498) |
| Total (ICER a adjusted) | $5129 ($5052) |
| PsA‐related health care costs, mean (SD) | |
| Total (unadjusted) | $6113 ($2431) |
| Inpatient admissions | $0 ($0) |
| Outpatient services | $151 ($524) |
| All outpatient pharmacy | $5962 ($2394) |
| Total (ICER a adjusted) | $3604 ($1486) |
| Ixekizumab costs, mean (SD) | |
| Total (unadjusted) | $5233 ($2497) |
| Out of pocket | $182 ($319) |
| Plan paid | $5050 ($2472) |
| Total (ICER a adjusted) | $2930 ($1399) |
Abbreviations: ICER, Institute for Clinical and Economic Review; PsA, psoriatic arthritis.
a
ICER discount factors are as follows: adalimumab discount factor = 31%, apremilast discount factor = 22%, certolizumab discount factor = 36%, etanercept discount factor = 31%, infliximab discount factor = 22%, ixekizumab discount factor = 44%, secukinumab discount factor = 38%, and ustekinumab discount factor = 27%. Drugs approved for PsA but not psoriasis (abatacept, golimumab, and tofacitinib) had no available discount factor and could not be adjusted.